Physician profile
Christopher Thomas Huhta
NPI 1104859032
$12,664.23
in general payments reported to CMS, 2019-2025
31 companies · $7,374 in 2025
The $7,374 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $666 · 2021: $690 · 2022: $967 · 2023: $1,216 · 2024: $1,142 · 2025: $7,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,095 · Food and Beverage: $3,188 · Travel and Lodging: $2,048 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,094.99 |
| Food and Beverage | $3,188.46 |
| Travel and Lodging | $2,048.46 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,048.46 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,804.63 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,038.51 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $593.89 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Glaxosmithkline, LLC. | $568.11 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $435.72 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $423.55 | 2020-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $422.27 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $306.37 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $237.87 | 2019-2024 | Yupelri |
| Amgen INC. | $86.28 | 2022-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $72.78 | 2019-2025 | Keytruda, Winrevair |
| Insmed, INC. | $71.52 | 2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $62.68 | 2019 | |
| Philips North America LLC | $62.20 | 2024-2025 | Vest Therapy Und, (8874) Incourage |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $58.98 | 2025 | Yupelri |
| Verona Pharma, INC. | $43.46 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $42.57 | 2019-2021 | |
| 3b Medical, INC. | $39.12 | 2025 | Luna |
| Jazz Pharmaceuticals INC. | $38.09 | 2021 | |
| Ethicon INC. | $29.96 | 2025 | Monarch Platform |
| Bard Peripheral Vascular, INC. | $25.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.74 | 2020-2022 | |
| United Therapeutics Corporation | $22.14 | 2021 | |
| Resmed Corp | $20.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.38 | 2023 | Ultomiris |
| Pfizer INC. | $15.37 | 2025 | |
| Phadia US INC. | $14.91 | 2024 | Immunocap |
| Shire North American Group INC | $13.62 | 2019 | |
| Covidien LP | $13.38 | 2020 | |
| Electromed, INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Huhta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.